Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. The company has developed a novel liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests (with a detection limit below 0.0001%, or one part-per-million). The improved sensitivity of the Foresight's MRD assays can provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with solid tumors and hematologic malignancies.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
04/27/23	$58,750,000	Series B	Agent Capital Bluebird Ventures Civilization Ventures Foresite Capital Pear Ventures Stanford University The University of Colorado Healthcare Innovation Fund	undisclosed